Pancreatic cancer is among the most dreaded: often with no early symptoms, it is diagnosed late and associated with an extremely poor prognosis. With the PACMAN project, supported by an ERC Proof of Concept Grant, Professor Thomas Baumert and his team are seeking to establish preclinical proof of concept for a new therapeutic approach.
An innovative therapy project
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent and aggressive form of pancreatic cancer. With a median survival of less than a year, even with treatment, the need for new therapies is urgent. Thanks to €150,000 in funding from the European Research Council (ERC), the PACMAN project will test the efficacy of an innovative therapeutic candidate in patient-derived models, a key step in accelerating the transition to clinical trials.
This new project is part of the close collaboration between Inserm, the University of Strasbourg, the University Hospitals of Strasbourg and the IHU Strasbourg to transform scientific discoveries into concrete innovations for the benefit of patients.
European funding: synonymous with excellence
Created by the European Union in 2007, the ERC is a prestigious and highly selective European program for funding excellent research projects in various categories. This is the fifth time in eight years that Thomas Baumert has been awarded funding, this time in the “ERC Proof of Concept Grant” category, which aims to accelerate the transfer of research work to applications.
Read the press release dated January 24, 2025, published by the University of Strasbourg (in French)
 |  |  |
